Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Micro Labs

- PMLiVE

US FTC requests more information on Pfizer’s proposed $43bn Seagen acquisition

The transaction would mark a significant boost to Pfizer’s oncology pipeline

- PMLiVE

BMS obtains global rights to Prothena’s Alzheimer’s drug in deal worth $2.2bn

The decision comes two years after the company paid $80m for opt-in rights to PRX005

- PMLiVE

Bristol Myers Squibb’s Sotyktu recommended by NICE for plaque psoriasis

An estimated 1.8 million people in the UK are affected by some form of the condition

- PMLiVE

Pfizer’s Litfulo approved by FDA as first treatment for adolescents with severe alopecia areata

Almost 20% of patients with the autoimmune disease are diagnosed before the age of 18

- PMLiVE

Pfizer’s Talzenna combination receives FDA approval for metastatic prostate cancer

Up to 20% of patients develop metastatic prostate cancer within five to seven years of diagnosis

- PMLiVE

Pfizer reports positive results for elranatamab in multiple myeloma

An estimated 35,000 new cases of multiple myeloma will be diagnosed in the US this year

- PMLiVE

BMS presents positive four-year results for Opdivo combination in lung cancer

NSCLC is the most common type of lung cancer, representing up to 85% of diagnoses

- PMLiVE

Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections

AMR has been declared by WHO as one of the top ten threats to global health

- PMLiVE

Pfizer’s RSV vaccine approved by FDA for older adults

RSV infections in older adults account for up to 160,000 hospitalisations each year in the US

- PMLiVE

COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP

Pfizer’s oral antiviral was granted accelerated approval in the US in December 2021

- PMLiVE

BMS and Janssen’s antithrombotic granted FDA fast track designation

The three indications include ischaemic stroke, acute coronary syndrome and atrial fibrillation

- PMLiVE

Bristol Myers Squibb presents positive results for idiopathic pulmonary fibrosis drug

About 100,000 people are living with the progressive condition in the US alone

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links